Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 15/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.55 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15601435 | 0.94 | ALOX5 (0.49) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15525724 | 0.87 | ALOX5 (0.59) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15601436 | 0.86 | CES2 (0.45) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL17154056 | 0.85 | ALOX5 (0.55) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15526096 | 0.82 | ALOX5 (0.52) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15529266 | 0.81 | HDAC6 (0.49) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL17154058 | 0.80 | ALOX5 (0.49) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15601467 | 0.79 | ALOX5 (0.58) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL3110221 | 0.79 | ALOX5 (0.61) | ALOX5EPHX2KCNT1HDAC6HDAC8 | |
| SCHEMBL15601450 | 0.78 | ALOX5 (0.57) | ALOX5EPHX2KCNT1HDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321750-B2 | ROR modulators and their uses | INNOV17 LLC (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321750-B2 | ROR modulators and their uses | INNOV17 LLC (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | INNOV17 LLC | 2015-10-08 | — | — | US | disclosed |
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | INNOV17 LLC | 2015-10-08 | — | — | US | disclosed |
| WO-2013159095-A1 | ROR MODULATORS AND THEIR USES | GAWECO ANDERSON (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284366-A1 | ROR MODULATORS AND THEIR USES | RORA, RORB, RORC | ALOX5 3468/4885EPHX2 926/4885KCNT1 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.